{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.3"},{"groupId":"OG001","value":"1.0"}]}],"title":"Reduction ≥ 30%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.3"},{"groupId":"OG001","value":"1.5"}]}],"title":"Reduction ≥ 20% but < 30%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.4"},{"groupId":"OG001","value":"3.5"}]}],"title":"Reduction ≥ 10% but < 20%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.4"},{"groupId":"OG001","value":"21.9"}]}],"title":"Reduction > 0% but < 10%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8"},{"groupId":"OG001","value":"62.7"}]}],"title":"Growth ≥ 0%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7"},{"groupId":"OG001","value":"9.5"}]}],"title":"Not assessed"}],"denoms":[{"counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"201"}],"units":"Participants"}],"description":"The magnitude of change from baseline in target lesion size in evaluable participants with scans was determined.","groups":[{"description":"Participants received 2 tablets of Sorafenib (2×200 mg) orally twice daily (12 hours apart without food), 28 days comprise a cycle","id":"OG000","title":"Sorafenib (Nexavar, BAY43-9006)"},{"description":"Participants received 2 tablets of Sorafenib-matching placebo orally twice daily (12 hours apart without food), 28 days comprise a cycle","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"PPS","reportingStatus":"POSTED","timeFrame":"From randomization of the first subject until the database cut-off (31 Aug 2012), study duration approximately three years","title":"Maximum Percent Reduction in Target Lesion Size Based on Central Assessment","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}